Beļģija - holandiešu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sotalolhydrochloride 160 mg - tablet - 160 mg - sotalolhydrochloride 160 mg - sotalol

Beļģija - holandiešu - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - sotalolhydrochloride 80 mg - tablet - 80 mg - sotalolhydrochloride 80 mg - sotalol

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (formaldehyde inactivated) (unii: au5c98u4bb) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (formaldehyde inactivated) - unii:c46xjt9fq9), influenza a virus a/darwin/6/2021 ivr-227 (h3n2) antigen (formaldehyde inactivated) (unii: f5qv7af326) (influenza a virus a/darwin/6/2021 ivr-227 (h3n2) hemagglutinin antigen (formaldehyde inactivated) - unii:n969qk7xd2), influenza b virus b/austria/1359417/2021 bvr-26 antigen - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (formaldehyde inactivated) 15 ug in 0.5 ml - fluarix quadrivalent is indicated for active immunization for the prevention of disease caused by influenza a subtype viruses and type b viruses contained in the vaccine [see description (11)] . fluarix quadrivalent is approved for use in persons aged 6 months and older. do not administer fluarix quadrivalent to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous administration of any influenza vaccine [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. available data from a pregnancy registry do not suggest an increased risk of major birth defects and miscarriage in individuals who received fluarix quadrivalent within 28 days prior to conception or during pregnancy (see d

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

id biomedical corporation of quebec - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (uv, formaldehyde inactivated) (unii: a5pts27urj) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (uv, formaldehyde inactivated) - unii:9ha5c4xl36), influenza a virus a/darwin/9/2021 ivr-228 (h3n2) antigen (uv, formaldehyde inactivated) (unii: p483j7gx6d) (influenza a virus a/darwin/9/2021 ivr-228 (h3n2) hemagglutinin antigen (uv, formaldehyde inactivated) - unii:grn94tp8yv), influenza b virus b/austria/1359417/2021 - influenza a virus a/singapore/gp1908/2015 ivr-180 (h1n1) hemagglutinin antigen (uv, formaldehyde inactivated) 15 ug in 0.5 ml - flulaval quadrivalent is indicated for active immunization for the prevention of disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. flulaval quadrivalent is approved for use in persons aged 6 months and older. do not administer flulaval quadrivalent to anyone with a history of severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. there are insufficient data on flulaval quadrivalent in pregnant women to inform vaccine-associated risks. a developmental toxicity study was performed in female rats administered flulaval quadrivalent prior to mating and during gestation and lactation p

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

merck sharp & dohme llc - human rotavirus a type g1p7(5) strain wi79 live antigen (unii: 25vc15141q) (human rotavirus a type g1p7(5) strain wi79 live antigen - unii:25vc15141q), human rotavirus a type g2p7(5) strain sc2 live antigen (unii: ju499is53h) (human rotavirus a type g2p7(5) strain sc2 live antigen - unii:ju499is53h), human rotavirus a type g3p7(5) strain wi78 live antigen (unii: 236ygp181o) (human rotavirus a type g3p7(5) strain wi78 live antigen - unii:236ygp181o), human rotavirus a type g4p7(5) strain brb live antigen - human rotavirus a type g1p7(5) strain wi79 live antigen 2200000 [iu] in 2 ml - rotateq® is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types g1, g2, g3, g4, and g9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rotateq should be administered between 6 and 12 weeks of age [see dosage and administration (2)] . a demonstrated history of hypersensitivity to any component of the vaccine. infants who develop symptoms suggestive of hypersensitivity after receiving a dose of rotateq should not receive further doses of rotateq. infants with severe combined immunodeficiency disease (scid) should not receive rotateq. post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered rotateq and later identified as having scid [see adverse reactions (6.2)] . infants with a history of intussusception should not receive rotateq. rotateq is not approved for individuals 32 weeks of age and older. no human or

Itālija - itāļu - Ministero della Salute

fatro s.p.a. - virus della sindrome del calo dell'ovodeposizione (eds)- 1976, inattivato, virus malattia di newcastle (pseudopeste aviarie), inattivato - virus della sindrome del calo dell'ovodeposizione (eds)- 1976, inattivato - 80 dp50 - dose protettiva per il 50% della popolazione; virus malattia di newcastle (pseudopeste aviarie), inattivato - 100 dp50 - dose protettiva per il 50% della popolazione, virus della sindrome del calo dell'ovodeposizione (eds)- 1976; inattivato - 80 dp50 - dose protettiva per il 50% della popolazione; virus malattia di newcastle (pseudopeste aviarie); inattivato - 100 dp50 - dose protettiva per il 50% della popolazione, adenovirus dell'eds inattivato - 80 dp50; virus della pseudopeste aviare inattivato - 100 dp50, virus della pseudopeste aviare inattivato - 100 dp50; adenovirus dell'eds inattivato - 80 dp50 - newcastle disease virus / paramyxovirus + avian adenovirus + avian adenovirus

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

boiron - viburnum opulus bark (unii: t1ug6h6805) (viburnum opulus bark - unii:t1ug6h6805) - painful menstruation with light flow* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

boiron - viburnum opulus bark (unii: t1ug6h6805) (viburnum opulus bark - unii:t1ug6h6805) - painful menstruation with light flow* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

boiron - viburnum opulus bark (unii: t1ug6h6805) (viburnum opulus bark - unii:t1ug6h6805) - painful menstruation with light flow* stop use and ask a doctor if symptoms persist for more than 3 days or worsen

Itālija - itāļu - Ministero della Salute

laboratorios hipra s.a. - virus della sindrome respiratoria e riproduttiva del suino (prrs), tipo 1, ceppo vp-046 bis, vivo e attenuato - virus della sindrome respiratoria e riproduttiva del suino (prrs), tipo 1, ceppo vp-046 bis, vivo e attenuato - 3.5 log 10 ccid 50 - log 10 dose infettante il 50% delle colture cellulari, virus della sindrome respiratoria e riproduttiva del suino (prrs); tipo 1; ceppo vp-046 bis; vivo e attenuato - 3.5 log 10 ccid 50 - log 10 dose infettante il 50% delle colture cellulari, virus inattivato della sindrome riproduttiva e respiratoria dei suini ceppo p120 - 10 cid 50 - porcine reproductive and respiratory syndrome (prrs) virus